Global Oral Hypoglycemic Agents and Insulin Analogues Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

Page: 97

Published Date: 05 Jan 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

According to our (Global Info Research) latest study, the global Oral Hypoglycemic Agents and Insulin Analogues market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Oral Hypoglycemic Agents and Insulin Analogues market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Oral Hypoglycemic Agents and Insulin Analogues market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Oral Hypoglycemic Agents and Insulin Analogues market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Oral Hypoglycemic Agents and Insulin Analogues market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (USD/Unit), 2018-2029
Global Oral Hypoglycemic Agents and Insulin Analogues market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (USD/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Oral Hypoglycemic Agents and Insulin Analogues
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Oral Hypoglycemic Agents and Insulin Analogues market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Sanofi-Aventis, Ganlee, Biocon, Novo Nordisk and Eli Lilly, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market Segmentation
Oral Hypoglycemic Agents and Insulin Analogues market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    Insulin Secretagogues
    Alpha-glucosidase Inhibitors
    Insulin Sensitizers

Market segment by Application
    Hospitals
    Drug Store
    Others

Major players covered
    Sanofi-Aventis
    Ganlee
    Biocon
    Novo Nordisk
    Eli Lilly
    Tonghua Dongbao
    United Laboratory
    Jiangsu Wanbang

Market segment by region, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)

The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Oral Hypoglycemic Agents and Insulin Analogues product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Oral Hypoglycemic Agents and Insulin Analogues, with price, sales, revenue and global market share of Oral Hypoglycemic Agents and Insulin Analogues from 2018 to 2023.
Chapter 3, the Oral Hypoglycemic Agents and Insulin Analogues competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Oral Hypoglycemic Agents and Insulin Analogues breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Oral Hypoglycemic Agents and Insulin Analogues market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Oral Hypoglycemic Agents and Insulin Analogues.
Chapter 14 and 15, to describe Oral Hypoglycemic Agents and Insulin Analogues sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Oral Hypoglycemic Agents and Insulin Analogues
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Insulin Secretagogues
        1.3.3 Alpha-glucosidase Inhibitors
        1.3.4 Insulin Sensitizers
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Hospitals
        1.4.3 Drug Store
        1.4.4 Others
    1.5 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size & Forecast
        1.5.1 Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018 & 2022 & 2029)
        1.5.2 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity (2018-2029)
        1.5.3 Global Oral Hypoglycemic Agents and Insulin Analogues Average Price (2018-2029)

2 Manufacturers Profiles
    2.1 Sanofi-Aventis
        2.1.1 Sanofi-Aventis Details
        2.1.2 Sanofi-Aventis Major Business
        2.1.3 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product and Services
        2.1.4 Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Sanofi-Aventis Recent Developments/Updates
    2.2 Ganlee
        2.2.1 Ganlee Details
        2.2.2 Ganlee Major Business
        2.2.3 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product and Services
        2.2.4 Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Ganlee Recent Developments/Updates
    2.3 Biocon
        2.3.1 Biocon Details
        2.3.2 Biocon Major Business
        2.3.3 Biocon Oral Hypoglycemic Agents and Insulin Analogues Product and Services
        2.3.4 Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Biocon Recent Developments/Updates
    2.4 Novo Nordisk
        2.4.1 Novo Nordisk Details
        2.4.2 Novo Nordisk Major Business
        2.4.3 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product and Services
        2.4.4 Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Novo Nordisk Recent Developments/Updates
    2.5 Eli Lilly
        2.5.1 Eli Lilly Details
        2.5.2 Eli Lilly Major Business
        2.5.3 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product and Services
        2.5.4 Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Eli Lilly Recent Developments/Updates
    2.6 Tonghua Dongbao
        2.6.1 Tonghua Dongbao Details
        2.6.2 Tonghua Dongbao Major Business
        2.6.3 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product and Services
        2.6.4 Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 Tonghua Dongbao Recent Developments/Updates
    2.7 United Laboratory
        2.7.1 United Laboratory Details
        2.7.2 United Laboratory Major Business
        2.7.3 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product and Services
        2.7.4 United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 United Laboratory Recent Developments/Updates
    2.8 Jiangsu Wanbang
        2.8.1 Jiangsu Wanbang Details
        2.8.2 Jiangsu Wanbang Major Business
        2.8.3 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product and Services
        2.8.4 Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Jiangsu Wanbang Recent Developments/Updates

3 Competitive Environment: Oral Hypoglycemic Agents and Insulin Analogues by Manufacturer
    3.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Manufacturer (2018-2023)
    3.2 Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Manufacturer (2018-2023)
    3.3 Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Manufacturer (2018-2023)
    3.4 Market Share Analysis (2022)
        3.4.1 Producer Shipments of Oral Hypoglycemic Agents and Insulin Analogues by Manufacturer Revenue ($MM) and Market Share (%): 2022
        3.4.2 Top 3 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer Market Share in 2022
        3.4.2 Top 6 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer Market Share in 2022
    3.5 Oral Hypoglycemic Agents and Insulin Analogues Market: Overall Company Footprint Analysis
        3.5.1 Oral Hypoglycemic Agents and Insulin Analogues Market: Region Footprint
        3.5.2 Oral Hypoglycemic Agents and Insulin Analogues Market: Company Product Type Footprint
        3.5.3 Oral Hypoglycemic Agents and Insulin Analogues Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region
        4.1.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Region (2018-2029)
        4.1.2 Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Region (2018-2029)
        4.1.3 Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Region (2018-2029)
    4.2 North America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018-2029)
    4.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018-2029)
    4.4 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018-2029)
    4.5 South America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018-2029)
    4.6 Middle East and Africa Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018-2029)

5 Market Segment by Type
    5.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2029)
    5.2 Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Type (2018-2029)
    5.3 Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Type (2018-2029)

6 Market Segment by Application
    6.1 Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2029)
    6.2 Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Application (2018-2029)
    6.3 Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Application (2018-2029)

7 North America
    7.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2029)
    7.2 North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2029)
    7.3 North America Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country
        7.3.1 North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Country (2018-2029)
        7.3.2 North America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Country (2018-2029)
        7.3.3 United States Market Size and Forecast (2018-2029)
        7.3.4 Canada Market Size and Forecast (2018-2029)
        7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe
    8.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2029)
    8.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2029)
    8.3 Europe Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country
        8.3.1 Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Country (2018-2029)
        8.3.2 Europe Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Country (2018-2029)
        8.3.3 Germany Market Size and Forecast (2018-2029)
        8.3.4 France Market Size and Forecast (2018-2029)
        8.3.5 United Kingdom Market Size and Forecast (2018-2029)
        8.3.6 Russia Market Size and Forecast (2018-2029)
        8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific
    9.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2029)
    9.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2029)
    9.3 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Market Size by Region
        9.3.1 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Region (2018-2029)
        9.3.2 Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Region (2018-2029)
        9.3.3 China Market Size and Forecast (2018-2029)
        9.3.4 Japan Market Size and Forecast (2018-2029)
        9.3.5 Korea Market Size and Forecast (2018-2029)
        9.3.6 India Market Size and Forecast (2018-2029)
        9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
        9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America
    10.1 South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2029)
    10.2 South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2029)
    10.3 South America Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country
        10.3.1 South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Country (2018-2029)
        10.3.2 South America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Country (2018-2029)
        10.3.3 Brazil Market Size and Forecast (2018-2029)
        10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa
    11.1 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2029)
    11.2 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2029)
    11.3 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Market Size by Country
        11.3.1 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Country (2018-2029)
        11.3.2 Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Country (2018-2029)
        11.3.3 Turkey Market Size and Forecast (2018-2029)
        11.3.4 Egypt Market Size and Forecast (2018-2029)
        11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
        11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics
    12.1 Oral Hypoglycemic Agents and Insulin Analogues Market Drivers
    12.2 Oral Hypoglycemic Agents and Insulin Analogues Market Restraints
    12.3 Oral Hypoglycemic Agents and Insulin Analogues Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry
    12.5 Influence of COVID-19 and Russia-Ukraine War
        12.5.1 Influence of COVID-19
        12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain
    13.1 Raw Material of Oral Hypoglycemic Agents and Insulin Analogues and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Oral Hypoglycemic Agents and Insulin Analogues
    13.3 Oral Hypoglycemic Agents and Insulin Analogues Production Process
    13.4 Oral Hypoglycemic Agents and Insulin Analogues Industrial Chain

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Oral Hypoglycemic Agents and Insulin Analogues Typical Distributors
    14.3 Oral Hypoglycemic Agents and Insulin Analogues Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Sanofi-Aventis Basic Information, Manufacturing Base and Competitors
    Table 4. Sanofi-Aventis Major Business
    Table 5. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Product and Services
    Table 6. Sanofi-Aventis Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 7. Sanofi-Aventis Recent Developments/Updates
    Table 8. Ganlee Basic Information, Manufacturing Base and Competitors
    Table 9. Ganlee Major Business
    Table 10. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Product and Services
    Table 11. Ganlee Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 12. Ganlee Recent Developments/Updates
    Table 13. Biocon Basic Information, Manufacturing Base and Competitors
    Table 14. Biocon Major Business
    Table 15. Biocon Oral Hypoglycemic Agents and Insulin Analogues Product and Services
    Table 16. Biocon Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 17. Biocon Recent Developments/Updates
    Table 18. Novo Nordisk Basic Information, Manufacturing Base and Competitors
    Table 19. Novo Nordisk Major Business
    Table 20. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Product and Services
    Table 21. Novo Nordisk Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 22. Novo Nordisk Recent Developments/Updates
    Table 23. Eli Lilly Basic Information, Manufacturing Base and Competitors
    Table 24. Eli Lilly Major Business
    Table 25. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Product and Services
    Table 26. Eli Lilly Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 27. Eli Lilly Recent Developments/Updates
    Table 28. Tonghua Dongbao Basic Information, Manufacturing Base and Competitors
    Table 29. Tonghua Dongbao Major Business
    Table 30. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Product and Services
    Table 31. Tonghua Dongbao Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 32. Tonghua Dongbao Recent Developments/Updates
    Table 33. United Laboratory Basic Information, Manufacturing Base and Competitors
    Table 34. United Laboratory Major Business
    Table 35. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Product and Services
    Table 36. United Laboratory Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 37. United Laboratory Recent Developments/Updates
    Table 38. Jiangsu Wanbang Basic Information, Manufacturing Base and Competitors
    Table 39. Jiangsu Wanbang Major Business
    Table 40. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Product and Services
    Table 41. Jiangsu Wanbang Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity (K Units), Average Price (USD/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 42. Jiangsu Wanbang Recent Developments/Updates
    Table 43. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Manufacturer (2018-2023) & (K Units)
    Table 44. Global Oral Hypoglycemic Agents and Insulin Analogues Revenue by Manufacturer (2018-2023) & (USD Million)
    Table 45. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Manufacturer (2018-2023) & (USD/Unit)
    Table 46. Market Position of Manufacturers in Oral Hypoglycemic Agents and Insulin Analogues, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
    Table 47. Head Office and Oral Hypoglycemic Agents and Insulin Analogues Production Site of Key Manufacturer
    Table 48. Oral Hypoglycemic Agents and Insulin Analogues Market: Company Product Type Footprint
    Table 49. Oral Hypoglycemic Agents and Insulin Analogues Market: Company Product Application Footprint
    Table 50. Oral Hypoglycemic Agents and Insulin Analogues New Market Entrants and Barriers to Market Entry
    Table 51. Oral Hypoglycemic Agents and Insulin Analogues Mergers, Acquisition, Agreements, and Collaborations
    Table 52. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Region (2018-2023) & (K Units)
    Table 53. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Region (2024-2029) & (K Units)
    Table 54. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Region (2018-2023) & (USD Million)
    Table 55. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Region (2024-2029) & (USD Million)
    Table 56. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Region (2018-2023) & (USD/Unit)
    Table 57. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Region (2024-2029) & (USD/Unit)
    Table 58. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2023) & (K Units)
    Table 59. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2024-2029) & (K Units)
    Table 60. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Type (2018-2023) & (USD Million)
    Table 61. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Type (2024-2029) & (USD Million)
    Table 62. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Type (2018-2023) & (USD/Unit)
    Table 63. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Type (2024-2029) & (USD/Unit)
    Table 64. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2023) & (K Units)
    Table 65. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2024-2029) & (K Units)
    Table 66. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Application (2018-2023) & (USD Million)
    Table 67. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Application (2024-2029) & (USD Million)
    Table 68. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Application (2018-2023) & (USD/Unit)
    Table 69. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Application (2024-2029) & (USD/Unit)
    Table 70. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2023) & (K Units)
    Table 71. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2024-2029) & (K Units)
    Table 72. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2023) & (K Units)
    Table 73. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2024-2029) & (K Units)
    Table 74. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Country (2018-2023) & (K Units)
    Table 75. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Country (2024-2029) & (K Units)
    Table 76. North America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Country (2018-2023) & (USD Million)
    Table 77. North America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Country (2024-2029) & (USD Million)
    Table 78. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2023) & (K Units)
    Table 79. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2024-2029) & (K Units)
    Table 80. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2023) & (K Units)
    Table 81. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2024-2029) & (K Units)
    Table 82. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Country (2018-2023) & (K Units)
    Table 83. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Country (2024-2029) & (K Units)
    Table 84. Europe Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Country (2018-2023) & (USD Million)
    Table 85. Europe Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Country (2024-2029) & (USD Million)
    Table 86. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2023) & (K Units)
    Table 87. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2024-2029) & (K Units)
    Table 88. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2023) & (K Units)
    Table 89. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2024-2029) & (K Units)
    Table 90. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Region (2018-2023) & (K Units)
    Table 91. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Region (2024-2029) & (K Units)
    Table 92. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Region (2018-2023) & (USD Million)
    Table 93. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Region (2024-2029) & (USD Million)
    Table 94. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2023) & (K Units)
    Table 95. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2024-2029) & (K Units)
    Table 96. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2023) & (K Units)
    Table 97. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2024-2029) & (K Units)
    Table 98. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Country (2018-2023) & (K Units)
    Table 99. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Country (2024-2029) & (K Units)
    Table 100. South America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Country (2018-2023) & (USD Million)
    Table 101. South America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Country (2024-2029) & (USD Million)
    Table 102. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2018-2023) & (K Units)
    Table 103. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Type (2024-2029) & (K Units)
    Table 104. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2018-2023) & (K Units)
    Table 105. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Application (2024-2029) & (K Units)
    Table 106. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Region (2018-2023) & (K Units)
    Table 107. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity by Region (2024-2029) & (K Units)
    Table 108. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Region (2018-2023) & (USD Million)
    Table 109. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Region (2024-2029) & (USD Million)
    Table 110. Oral Hypoglycemic Agents and Insulin Analogues Raw Material
    Table 111. Key Manufacturers of Oral Hypoglycemic Agents and Insulin Analogues Raw Materials
    Table 112. Oral Hypoglycemic Agents and Insulin Analogues Typical Distributors
    Table 113. Oral Hypoglycemic Agents and Insulin Analogues Typical Customers
List of Figures
    Figure 1. Oral Hypoglycemic Agents and Insulin Analogues Picture
    Figure 2. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Type in 2022
    Figure 4. Insulin Secretagogues Examples
    Figure 5. Alpha-glucosidase Inhibitors Examples
    Figure 6. Insulin Sensitizers Examples
    Figure 7. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Figure 8. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Application in 2022
    Figure 9. Hospitals Examples
    Figure 10. Drug Store Examples
    Figure 11. Others Examples
    Figure 12. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 13. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 14. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity (2018-2029) & (K Units)
    Figure 15. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price (2018-2029) & (USD/Unit)
    Figure 16. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Manufacturer in 2022
    Figure 17. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Manufacturer in 2022
    Figure 18. Producer Shipments of Oral Hypoglycemic Agents and Insulin Analogues by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
    Figure 19. Top 3 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer (Consumption Value) Market Share in 2022
    Figure 20. Top 6 Oral Hypoglycemic Agents and Insulin Analogues Manufacturer (Consumption Value) Market Share in 2022
    Figure 21. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Region (2018-2029)
    Figure 22. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Region (2018-2029)
    Figure 23. North America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018-2029) & (USD Million)
    Figure 24. Europe Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018-2029) & (USD Million)
    Figure 25. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018-2029) & (USD Million)
    Figure 26. South America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018-2029) & (USD Million)
    Figure 27. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Consumption Value (2018-2029) & (USD Million)
    Figure 28. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Type (2018-2029)
    Figure 29. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Type (2018-2029)
    Figure 30. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Type (2018-2029) & (USD/Unit)
    Figure 31. Global Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Application (2018-2029)
    Figure 32. Global Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Application (2018-2029)
    Figure 33. Global Oral Hypoglycemic Agents and Insulin Analogues Average Price by Application (2018-2029) & (USD/Unit)
    Figure 34. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Type (2018-2029)
    Figure 35. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Application (2018-2029)
    Figure 36. North America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Country (2018-2029)
    Figure 37. North America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Country (2018-2029)
    Figure 38. United States Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 39. Canada Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 40. Mexico Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 41. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Type (2018-2029)
    Figure 42. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Application (2018-2029)
    Figure 43. Europe Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Country (2018-2029)
    Figure 44. Europe Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Country (2018-2029)
    Figure 45. Germany Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 46. France Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 47. United Kingdom Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 48. Russia Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 49. Italy Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 50. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Type (2018-2029)
    Figure 51. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Application (2018-2029)
    Figure 52. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Region (2018-2029)
    Figure 53. Asia-Pacific Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Region (2018-2029)
    Figure 54. China Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 55. Japan Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 56. Korea Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 57. India Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 58. Southeast Asia Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 59. Australia Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 60. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Type (2018-2029)
    Figure 61. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Application (2018-2029)
    Figure 62. South America Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Country (2018-2029)
    Figure 63. South America Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Country (2018-2029)
    Figure 64. Brazil Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 65. Argentina Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 66. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Type (2018-2029)
    Figure 67. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Application (2018-2029)
    Figure 68. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Sales Quantity Market Share by Region (2018-2029)
    Figure 69. Middle East & Africa Oral Hypoglycemic Agents and Insulin Analogues Consumption Value Market Share by Region (2018-2029)
    Figure 70. Turkey Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 71. Egypt Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 72. Saudi Arabia Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 73. South Africa Oral Hypoglycemic Agents and Insulin Analogues Consumption Value and Growth Rate (2018-2029) & (USD Million)
    Figure 74. Oral Hypoglycemic Agents and Insulin Analogues Market Drivers
    Figure 75. Oral Hypoglycemic Agents and Insulin Analogues Market Restraints
    Figure 76. Oral Hypoglycemic Agents and Insulin Analogues Market Trends
    Figure 77. Porters Five Forces Analysis
    Figure 78. Manufacturing Cost Structure Analysis of Oral Hypoglycemic Agents and Insulin Analogues in 2022
    Figure 79. Manufacturing Process Analysis of Oral Hypoglycemic Agents and Insulin Analogues
    Figure 80. Oral Hypoglycemic Agents and Insulin Analogues Industrial Chain
    Figure 81. Sales Quantity Channel: Direct to End-User vs Distributors
    Figure 82. Direct Channel Pros & Cons
    Figure 83. Indirect Channel Pros & Cons
    Figure 84. Methodology
    Figure 85. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Sanofi-Aventis
Ganlee
Biocon
Novo Nordisk
Eli Lilly
Tonghua Dongbao
United Laboratory
Jiangsu Wanbang

Related Reports

Global Oral Hypoglycemic Agents and Insulin Analogues Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Global Oral Hypoglycemic Agents and Insulin Analogues Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Oral Hypoglycemic Agents and Insulin Analogues market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period.

Product Tags

Oral Hypoglycemic Agents and Insulin Analogues

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>